^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    20h
    ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P1/2, N=41, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1/2 trial
    |
    Meiyouheng (becotatug vedotin) • Qibeian (iparomlimab/tuvonralimab)
    22h
    HCC-SIGHT: A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=350, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Stivarga (regorafenib) • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    1d
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)
    6d
    Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    7d
    A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab)
    7d
    Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Lenvima (lenvatinib) • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    15d
    A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    19d
    QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Qibeian (iparomlimab/tuvonralimab)
    20d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    22d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    22d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Huazhong University of Science and Technology
    New P2 trial
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    23d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P4, N=55, Not yet recruiting, Huazhong University of Science and Technology
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)